Garcinol has been previously tested in pancreatic cancer and breast cancer, in conjunction with other anti-cancer agents namely gemcitabine, curcumin and anti-ERBB2 antibody [63–65]. This evidence concerns the gene ERBB2 and pancreatic neoplasm.